Video

Dr. Thompson on the Rationale for the BRUIN Study in Richter Transformation

Meghan Thompson, MD, discusses the rationale for the phase 1/2 BRUIN study in patients with Richter transformation. 

Meghan Thompson, MD, third-year fellow, Hematology and Medical Oncology, Memorial Sloan Kettering Cancer Center, discusses the rationale for the phase 1/2 BRUIN study (NCT03740529) in patients with Richter transformation. 

Richter transformation is a rare, but serious complication that arises in a small subgroup of patients with CLL, Thompson says. Moreover, the disease can transform into a more aggressive lymphoma, such as diffuse large B-cell lymphoma or Hodgkin lymphoma, Thompson adds. Patients with Richter transformation are considered high risk and have an estimated overall survival ofbetween 3 and 11 months, Thompson explains.

Moreover, the standard of care treatment is not clear for these patients, Thompson continues. However, the BRUIN study evaluated a novel approach to treating patients with Richter transformation with pirtobrutinib (LOXO-305), Thompson concludes.

Related Videos
Funda Meric-Bernstam, MD
Bhavana Pothuri, MD
Kristen Spencer, DO
Laurence Albigès, MD, PhD
Nirav Shah, MD, MSHP, discusses evaluating zamtocabtagene autoleucel in patients with relapsed/refractory diffuse large B-cell lymphoma.
Bhagirathbhai Dholaria, MBBS
Sairah Ahmed, M.D
Joshua K. Sabari, MD
Barry W. Goy, MD
Fred Saad, CQ, MD, FRCS, FCAHS, director, Prostate Cancer Research, Montreal Cancer Institute, Centre Hospitalier de l’Université de Montréal; full professor, Department of Surgery, Université de Montréal; uro-oncologist, Urology Department, University of Montreal Health Center